Abstract
Background- There is a lack of information on the incidence and predictors of early mortality at 30 days and late mortality between 30 days and 1 year after transcatheter aortic valve implantation (TAVI) with the self-expanding CoreValve Revalving prosthesis. Methods and Results- A total of 663 consecutive patients (mean age 81.0±7.3 years) underwent TAVI with the third generation 18-Fr CoreValve device in 14 centers. Procedural success and intraprocedural mortality were 98% and 0.9%, respectively. The cumulative incidences of mortality were 5.4% at 30 days, 12.2% at 6 months, and 15.0% at 1 year. The incidence density of mortality was 12.3 per 100 person-year of observation. Clinical and hemodynamic benefits observed acutely after TAVI were sustained at 1 year. Paravalvular leakages were trace to mild in the majority of cases. Conversion to open heart surgery (odds ratio [OR] 38.68), cardiac tamponade (OR 10.97), major access site complications (OR 8.47), left ventricular ejection fraction
Original language | English |
---|---|
Pages (from-to) | 299-308 |
Number of pages | 10 |
Journal | Circulation |
Volume | 123 |
Issue number | 3 |
DOIs | |
Publication status | Published - Jan 25 2011 |
Keywords
- aortic stenosis
- aortic valve
- transcatheter aortic valve implantation
- valve prosthesis
ASJC Scopus subject areas
- Physiology (medical)
- Cardiology and Cardiovascular Medicine